Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial

Ildiko Lingvay (Lead / Corresponding author), Andrei-Mircea Catarig, Juan P. Frias, Harish Kumar, Nanna L. Lausvig, Carel W. le Roux, Desirée Thielke, Adie Viljoen, Rory McCrimmon

    Research output: Contribution to journalArticlepeer-review

    165 Citations (Scopus)
    1755 Downloads (Pure)

    Fingerprint

    Dive into the research topics of 'Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial'. Together they form a unique fingerprint.

    Pharmacology, Toxicology and Pharmaceutical Science

    Keyphrases

    Medicine and Dentistry